Dospir

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dospir

Quick Facts

Property Description
Active ingredients Ipratropium bromide, Salbutamol
Form Nebuliser solution
Pharmacological class Combination Bronchodilator
General purpose Relief of Bronchospasm
Origin Synthetic (derived)

Defining Dospir: A Combination Bronchodilator Entity

Dospir is a synthetic, prescription-only combination medicinal product used to relieve breathing difficulties, having been clinically recognized for its reliable action on the airways. Its primary classification is as a combination bronchodilator, a pharmacological class designed to widen the air passages in the lungs. Combining an anticholinergic agent with a beta2-agonist, as found in Dospir, improves lung function more effectively than using either agent alone, demonstrating a complementary effect for patients. This combination approach ensures the medicine addresses the physiological signals contributing to the tightening of the bronchial smooth muscle more comprehensively.

Core Composition and Pharmaceutical Form

The medicine's formulation contains two primary active ingredients: ipratropium bromide and salbutamol (also known as albuterol), which are supplied in the form of a sterile, ready-to-use nebuliser solution. The preparation is specifically designed for use in a nebulising device, differentiating it from formulations intended for metered-dose inhalers (MDIs). This dual therapy promotes bronchodilation through two distinct pharmacological actions. This combination, consisting of an anticholinergic agent and a beta2-adrenergic agonist, provides a robust, two-pronged strategy for maintaining open airways. The solution is administered via the inhalation route, ensuring the synthetic compounds are delivered directly to the lower respiratory tract.

General Purpose and Benefit for Airflow

The general purpose of this combination product is to provide effective, immediate relief from the sudden tightening of the air passages, a common event known as bronchospasm. By employing its dual mechanism, which involves both relaxing the muscle and preventing further constriction, Dospir facilitates the bronchodilation process. The overall benefit is the rapid and substantial improvement of airflow, typically employed when a patient requires simultaneous action from both classes of bronchodilator to alleviate the sensation of breathlessness caused by airway obstruction.

What side effects are possible with Dospir?

Possible Side Effects and Safety Information

The safety profile for this combination bronchodilator is officially documented by regulatory authorities, classifying possible adverse reactions by the frequency observed in clinical use and post-marketing data. Effects are categorized across various physiological systems.


Frequency-Classified Adverse Reactions

The regulatory classification of reactions includes:

  • Common Reactions: Adverse effects documented to occur in at least 1 in 100 patients. These often include Headache, Dry mouth, and Tremor, as well as Nausea and Cough.
  • Uncommon Reactions: These reactions are observed less frequently and include effects such as Palpitations, Tachycardia (fast heart rate), and Dizziness. Paradoxical bronchospasm, a sudden tightening of the airways, is also documented in this category.
  • Rare Reactions: Effects reported infrequently, such as Glaucoma (increased pressure in the eye), Ischaemia of the myocardium (heart muscle events), Atrial fibrillation, and Hypokalaemia (low potassium levels).

Serious Safety Considerations

The official labeling highlights specific serious safety concerns. Paradoxical bronchospasm may occur immediately after administration. Rare but serious events include Acute Narrow-Angle Glaucoma if the nebulised mist contacts the eyes, and rare Immediate Hypersensitivity Reactions such as anaphylaxis or angioedema. Certain cardiovascular events like Ischaemia of the myocardium are also formally documented.


Population-Specific Safety Notes

Official safety statements note that caution is required in patients with pre-existing conditions, including narrow-angle Glaucoma, Prostatic hyperplasia, or Bladder neck obstruction. The product is strictly contraindicated in individuals with Hypertrophic obstructive cardiomyopathy or Tachyarrhythmia.

Furthermore, the label specifies that effects like Tremor and Tachycardia are more commonly observed at the initiation of treatment, while Hypokalaemia is a risk associated with high doses or long-term use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with this combination product is considered a potentially lethal polydrug overdose and requires immediate emergency action. The primary danger comes from two distinct, life-threatening toxicities associated with the active ingredients.

Acute Overdose Risks

Active Component Immediate Risk Symptoms
Hydrocodone Serious or potentially fatal Respiratory and CNS Depression Slow/shallow breathing, stupor, coma, pinpoint pupils, cold/clammy skin, circulatory failure.
Acetaminophen Dose-dependent, potentially fatal Hepatic Necrosis (Liver Failure) Early, non-specific symptoms may include nausea, vomiting, diaphoresis (sweating), and general malaise.

When to Seek Immediate Medical Help

Call your local emergency number or Poison Control Center immediately if you suspect an overdose, even if the person is not experiencing obvious signs or symptoms. Because initial symptoms of acetaminophen toxicity can be mild, but the resulting liver damage is delayed and potentially fatal, prompt medical attention is required right away.

Treatment in a healthcare setting addresses both components: naloxone is used as a specific antidote to reverse the life-threatening respiratory depression caused by the opioid, while measures like activated charcoal and the specific antidote N-acetylcysteine are utilized to counter the potential liver damage from acetaminophen.

Therapeutic Uses of Dospir

Dospir is indicated to help manage symptoms of specific chronic respiratory conditions. It contains a combination of active ingredients that work to support improved breathing.

Quick Facts on Dospir's Uses

  • Chronic Obstructive Pulmonary Disease (COPD): Dospir is approved for the maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease, including chronic bronchitis and emphysema. It is intended to help improve baseline lung function.
  • Asthma Exacerbations: The medication is also used in the management of severe, acute asthma exacerbations, often in combination with other therapeutic agents, to assist in the prompt relief of symptoms.

Its therapeutic effect is centered on addressing the reduced airflow associated with these obstructive airway diseases. Patients considering this medication should consult with a healthcare professional regarding the approved indications.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dospir?

Eligibility for Dospir (ipratropium bromide/salbutamol nebuliser solution) is strictly governed by regulatory classifications based on the drug's established safety profile in specific patient populations.


Contraindications: Who Must Not Use Dospir

Use is absolutely prohibited (contraindicated) for patients with a known hypersensitivity or allergy to the active ingredients (ipratropium bromide or salbutamol), or to atropine and its derivatives. Dospir is also contraindicated in patients diagnosed with hypertrophic obstructive cardiomyopathy or certain tachyarrhythmias (abnormally fast heart rhythms).


Age and Special Population Restrictions

  • Approved Ages: The medicine is generally approved for adults and adolescents (aged 12 years and over).
  • Pediatric Use: Use is not recommended in children under 12 years because the safety and efficacy for this combination product have not been established in this age group.
  • Comorbidities: Use requires caution in patients with or predisposed to narrow-angle glaucoma or urinary outflow tract obstruction (e.g., prostatic hypertrophy).
  • Reproductive Status: For both pregnancy and lactation, use is restricted and requires a formal justification that the potential benefit outweighs the risk to the fetus or infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Dospir (Ipratropium bromide and Salbutamol) based on additive effects and antagonism related to its two active components.

Documented Interaction Patterns

Interaction Entity Official Interaction Description
Non-cardioselective Beta-blockers Co-administration inhibits the bronchodilator effect of the Salbutamol component and may lead to a potentially severe reduction in efficacy.
Other Anticholinergic Agents There is a risk of additive systemic effects; co-administration is generally not recommended as the safety of this combination has not been established.
Other beta-adrenergic Agonists May increase the risk of adverse cardiovascular effects; this combination should be avoided due to the potential for reinforced effects.
MAOIs or TCAs The action of the Salbutamol component on the cardiovascular system may be potentiated, requiring administration with extreme caution due to increased cardiovascular risk.
Diuretics, Xanthines, Steroids Concomitant treatment can enhance the risk of hypokalaemia (low potassium levels) resulting from beta-agonist therapy.
Halogenated Anesthetics May increase the susceptibility to the cardiovascular effects of Salbutamol, increasing the risk of serious ventricular arrhythmia.

Administration Restriction

Regulatory guidance strongly recommends against mixing the nebulizer solution with any other drugs in the same nebulizer. Furthermore, the risk of hypokalaemia is officially noted to be aggravated by hypoxia in patients co-administered with diuretics, xanthines, or steroids.

Mechanism of Action

Dual Control of Airway Smooth Muscle Tone

The mechanism centers on simultaneous modulation of the mathbfSympathetic and mathbfParasympathetic nervous system pathways that govern bronchial smooth muscle. One component selectively activates mathbfbeta2 Adrenergic Receptors to promote a reduction in contractile force, while the other blocks mathbfMuscarinic Receptors to inhibit nerve-driven constriction and glandular secretion. This complementary action directly targets the two primary neurological forces controlling the diameter of the air passages.


️ Complementary Modulation of Intracellular Signaling

The drug initiates distinct yet converging intracellular signaling cascades. The beta2 activation increases the messenger cyclic AMP (cAMP), leading to the inhibition of the muscle's contractile machinery. Simultaneously, the muscarinic blockade prevents the rise of intracellular calcium and other messengers essential for contraction and secretion. This dual pathway modulation results in a reduction in contractile force and decreased glandular secretion, leading to the physiological expansion of the air tubes.

Dosage and Administration Information

The administration of Dospir is governed by its design as a combination inhalation solution, requiring delivery via a nebulizer device directly into the respiratory tract. Usage involves the use of one 3 mL unit-dose vial per single treatment, which provides the standard dose of both ipratropium bromide and salbutamol. The solution is exclusively for oral inhalation and must not be swallowed or injected.

Administration Protocol and Frequency

This medication is integrated into the overall treatment plan according to two principal patterns: it is used for long-term maintenance of bronchospasm associated with chronic obstructive diseases, and it is also employed intermittently for the management of acute exacerbations. The standard frequency for routine maintenance involves administering the solution three or four times daily, with a procedural constraint that treatments must be separated by a minimum interval of four to six hours to prevent exceeding the maximum daily limit. Established guidelines specify that the total number of inhalations should not exceed eight treatments within 24 hours.

Preparation and Population Rules

Instructions specify that the contents of the sterile unit-dose vial be used immediately after opening and generally administered undiluted using a standard jet nebulizer. Regarding specific populations, dosing is generally restricted to patients 12 years of age and older, with no specific dosage modifications typically designated for older adults based on age alone. Any residual solution must be discarded immediately after use, as the vial contents are for a single treatment session only.

Recent Clinical Evidence

Research evidence / Overview of studies for Dospir


Evidence for Stable, Long-Term Management of COPD

The research base for this combination therapy was studied for individuals with long-term respiratory conditions, primarily focusing on Chronic Obstructive Pulmonary Disease (COPD). These studies typically involved adult patients, often those with moderate to severe airflow limitations, and research examined outcomes related to measured functional changes in the airways. Researchers measured objective results such as the volume of air a patient could force out in one second (FEV1), which is relevant in evidence describing how symptoms are measured. Trials also monitored patient-reported outcomes that described perceived discomfort and daily functioning or activity level.

Findings describe patterns observed in the studies regarding functional measurements of lung capacity when comparing groups who received the combination therapy versus a placebo or an individual component alone. The results contribute to understanding how patients reported their experience of breathing changes over the study periods.

Comparison to Single-Agent Therapy and Placebo

The primary goal of many trials was to assess the combination agent in relation to its individual components and placebo, and studies monitored whether the combination of actions was observed with different patterns of change in lung function measurements. The evidence contributes to the broader evidence landscape by exploring how the two different bronchodilator mechanisms were observed in relation to each other in this setting.


Evidence for Managing Acute Airflow Obstruction (Exacerbations)

The combination was studied for use in conditions associated with acute or disruptive episodes, specifically severe flares or exacerbations of asthma and COPD. This evidence was derived from settings with varying symptom burdens, such as hospital emergency departments, where research explored short-term changes.

Long-Term Studies and Follow-up Durations

Most published Randomized Controlled Trials are relevant in trials assessing short-term or episodic symptom patterns. Research designs often limited follow-up periods to single-dose administration or intermediate terms, frequently lasting only a few weeks to three months. Long-term effects are not fully established by the existing high-certainty RCTs.

Frequently Asked Questions (FAQ)

Common questions about Dospir (FAQ)

Q: What should I do if I miss a dose of Dospir?

Official instructions for similar combination inhalers indicate that the missed dose is typically administered as soon as possible. Following this, the patient may then return to the regularly scheduled dosing time.


Q: How do I properly clean and maintain the nebulizer device used for Dospir?

Government-published patient information on nebulizer use suggests that the medicine cup and the mouthpiece or mask be washed with warm water and mild soap after each treatment. Rinsing the parts thoroughly and allowing them to air dry are generally recommended steps, but patients should always refer to the specific cleaning instructions for their nebulizer device.


Q: Can Dospir be taken during pregnancy or while breastfeeding?

Official labeling indicates that use during pregnancy is restricted. It is typically only considered when a healthcare professional determines the potential benefit is greater than the potential risk to the fetus. When considering use while breastfeeding, official information advises that the clinical need for the drug must be weighed against the potential benefits for the nursing infant.


Q: How long does it take for Dospir to start working after inhalation?

Based on clinical studies cited in official product information, the medication is designed for rapid action. Clinically significant widening of the airways (bronchodilation) may begin within 15 minutes of administration, with the maximum effect generally observed within 1 to 3 hours.


Q: Is it safe to drive after taking Dospir?

Official warnings note that side effects such as dizziness, headache, or blurred vision may occur, particularly if the nebulized mist contacts the eyes. If these side effects occur, caution is generally recommended before driving or engaging in activities that require full concentration.


Q: Are there specific storage instructions for Dospir, like refrigeration?

Official storage requirements state that the medication should be stored at or below 25 C. The unit-dose vials are generally provided within a protective foil pouch, and maintaining the packaging helps to protect the solution from light and moisture.


Q: Is Dospir available as a tablet or only as a nebuliser solution?

Official regulatory documents define Dospir as a sterile, ready-to-use nebulizer solution specifically intended for oral inhalation. No other pharmaceutical forms, such as a tablet or an MDI, are listed or approved under the official product label.


Q: What is the specific volume of the unit-dose vial?

The official product documentation and prescribing information confirm that the medication is supplied in a 3 mL unit-dose vial for a single treatment session.


Q: What is the maximum daily dosage of Dospir?

The official product labeling establishes a maximum usage frequency. The total number of inhalations is restricted to eight treatments within a 24-hour period.

How should Dospir be stored and disposed of?

How to Store and Dispose of Dospir?

Regulatory documents define specific conditions for storing and handling Dospir (Budesonide and Formoterol fumarate dihydrate) inhalation powder to maintain its stability.

Official Storage Requirements

Requirement Classification
Maximum Temperature Do not store above 25 C.
Unopened Shelf Life 3 years.
In-Use Stability 6 months after opening the foil wrap.
Handling Keep the mouthpiece cover closed to protect the powder.

Disposal Guidelines

There are no explicit, end-user disposal instructions detailed on the product label. All unused or expired medicine must be disposed of according to official local and national pharmaceutical return schemes or general regulatory procedures to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dospir found in:

A-Z Index: